Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
AskTraders may earn a commission when you click through to a broker.
BridgeBio Wins FDA Priority Review for Oral Achondroplasia Drug, Decision Due February
The FDA has accepted BridgeBio's application for oral infigratinib in children with achondroplasia and granted Priority Review, setting a decision date of the 4th of February. Shares rose modestly in US trading.
The US Food and Drug Administration has accepted BridgeBio’s application for oral infigratinib in children with achondroplasia and granted it Priority Review, the company said on Tuesday. BridgeBio (NASDAQ: BBIO) is a biotech company; achondroplasia is a bone growth condition affecting between 1 in 15,000 and 1 in 40,000 newborns, according to the US National Institutes of Health’s MedlinePlus.
BBIO traded at $67.37 in delayed US trading by 5.30pm London time today, up $1.23, or 1.86%, from yesterday’s close of $66.14. That is an intraday quote rather than a close, and the shares remain about 28% below their 52-week high of $93.415, reached on the 9th of July.
BBIO.US
The FDA accepted the new drug application for filing and set a PDUFA date, its target date for a decision, of the 4th of February 2027. Priority Review is not approval, so that date is the next binary regulatory event for the drug.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Justin To, CEO of BridgeBio Skeletal Dysplasias, said in the release:
Being granted Priority Review means we are one step closer to potential FDA approval of the first oral treatment option for children with achondroplasia.
Justin To, CEO of BridgeBio Skeletal Dysplasias
The filing rests on the Phase 3 PROPEL 3 trial, published in the New England Journal of Medicine. It met its primary endpoint, annualised height velocity at week 52, with a mean treatment difference of 2.10 cm a year (p<0.0001), and also hit its key secondary measure, height Z-score. BridgeBio said the drug was well tolerated, with no discontinuations or serious adverse events related to the study drug.
BridgeBio’s daily closes, 1st of July to the 5th of October 2026: shares fell from a July peak of $90.17 to $66.14 before the news.
BridgeBio says that, if approved, infigratinib would be the first and only oral therapy for children with achondroplasia. Existing options are injections: BioMarin’s Voxzogo, approved in 2021 and given daily, and Ascendis Pharma’s Yuviwel, a once-weekly treatment approved by the FDA in February 2026.
Sponsored
The company anticipates a US launch upon approval. The next fixed point for the shares, still well below their July highs, is the FDA’s decision date of the 4th of February.
The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.
Stay ahead of the markets
Sign up to our free Morning Markets email, every weekday before the open.
Stay ahead of the markets
Morning Markets
Weekdays
FTSE, overnight moves and what matters before the open.
Show personalised advertising and content, and measure how adverts and content perform
Learn about our audience and develop and improve our services
Learn more
Advertising pays for our free market news, analysis and trading tools.
If you accept, we and our partners may also match and combine data from other sources, link your devices, and identify your device from its characteristics, precise location or by actively scanning it. Some partners rely on legitimate interest rather than consent for certain purposes; you can object in the full list.
You can reject, or choose which purposes to allow under Manage options. Your choice is kept for this browser and you can change it at any time. See every purpose and partner
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
We and our advertising partners use cookies to show relevant advertising and measure its performance. You can opt out of the sale or sharing of your personal information, and of personalised advertising, at any time using the link below.
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner